PMID- 30863759
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2307-8960 (Print)
IS  - 2307-8960 (Electronic)
IS  - 2307-8960 (Linking)
VI  - 7
IP  - 5
DP  - 2019 Mar 6
TI  - Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 
      5-fluorouracil regimen for advanced gastric cancer: A systematic review and 
      meta-analysis.
PG  - 600-615
LID - 10.12998/wjcc.v7.i5.600 [doi]
AB  - BACKGROUND: As the first-line regimens for the treatment of advanced gastric 
      cancer, both docetaxel, cisplatin, and 5-fluorouracil (DCF) and epirubicin, 
      cisplatin, and 5-fluorouracil (ECF) regimens are commonly used in clinical 
      practice, but there is still controversy about which is better. AIM: To compare 
      the efficacy and safety of DCF and ECF regimens by conducting this meta-analysis. 
      METHODS: Computer searches in PubMed, EMBASE, Ovid MEDLINE, Science Direct, Web 
      of Science, The Cochrane Library and Scopus were performed to find the clinical 
      studies of all comparisons between DCF and ECF regimens. We used progression-free 
      survival (PFS), overall survival (OS), objective response rate (ORR), disease 
      control rate (DCR), and adverse effects (AEs) as endpoints for analysis. RESULTS: 
      Our meta-analysis included seven qualified studies involving a total of 598 
      patients. The pooled hazard ratios between the DCF and ECF groups were comparable 
      in PFS (95%CI: 0.58-1.46, P = 0.73), OS (95%CI: 0.65-1.10, P = 0.21), and total 
      AEs (95%CI: 0.93-1.29, P = 0.30). The DCF group was significantly better than the 
      ECF group in terms of ORR (95%CI: 1.13-1.75, P = 0.002) and DCR (95%CI: 
      1.03-1.41, P = 0.02). However, the incidence rate of grade 3-4 AEs was also 
      greater in the DCF group than in the ECF group (95%CI: 1.16-1.88, P = 0.002), 
      especially for neutropenia and febrile neutropenia. CONCLUSION: With better ORR 
      and DCR values, the DCF regimen seems to be more suitable for advanced gastric 
      cancer than the ECF regimen. However, the higher rate of AEs in the DCF group 
      still needs to be noticed.
FAU - Li, Bo
AU  - Li B
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang 330006, Jiangxi Province, China.
FAU - Chen, Lian
AU  - Chen L
AD  - Jiangxi Medical College, Nanchang University, Nanchang 330006, Jiangxi Province, 
      China.
FAU - Luo, Hong-Liang
AU  - Luo HL
AD  - Department of Gastrointestinal Surgery, The Second Affiliated Hospital of 
      Nanchang University, Nanchang 330006, Jiangxi Province, China.
FAU - Yi, Feng-Ming
AU  - Yi FM
AD  - Department of Digestive Oncology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang 330006, Jiangxi Province, China.
FAU - Wei, Yi-Ping
AU  - Wei YP
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang 330006, Jiangxi Province, China.
FAU - Zhang, Wen-Xiong
AU  - Zhang WX
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang 330006, Jiangxi Province, China. zwx123dr@126.com.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Clin Cases
JT  - World journal of clinical cases
JID - 101618806
PMC - PMC6406203
OTO - NOTNLM
OT  - 5-fluorouracil
OT  - Chemotherapy
OT  - Cisplatin
OT  - Docetaxel
OT  - Epirubicin
OT  - Gastric cancer
COIS- Conflict-of-interest statement: The authors deny any conflict of interest.
EDAT- 2019/03/14 06:00
MHDA- 2019/03/14 06:01
PMCR- 2019/03/06
CRDT- 2019/03/14 06:00
PHST- 2018/10/31 00:00 [received]
PHST- 2018/12/20 00:00 [revised]
PHST- 2018/12/29 00:00 [accepted]
PHST- 2019/03/14 06:00 [entrez]
PHST- 2019/03/14 06:00 [pubmed]
PHST- 2019/03/14 06:01 [medline]
PHST- 2019/03/06 00:00 [pmc-release]
AID - 10.12998/wjcc.v7.i5.600 [doi]
PST - ppublish
SO  - World J Clin Cases. 2019 Mar 6;7(5):600-615. doi: 10.12998/wjcc.v7.i5.600.